Market closedNon-fractional
BridgeBio Pharma/BBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BridgeBio Pharma
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Ticker
BBIO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Palo Alto, United States
Employees
553
Website
bridgebio.com
BridgeBio Pharma Metrics
BasicAdvanced
$5B
Market cap
-
P/E ratio
-$3.18
EPS
1.03
Beta
-
Dividend rate
Price and volume
Market cap
$5B
Beta
1.03
Financial strength
Current ratio
6.371
Quick ratio
6.141
Long term debt to equity
-166.294
Total debt to equity
-166.732
Interest coverage (TTM)
-5.59%
Management effectiveness
Return on assets (TTM)
-40.08%
Return on equity (TTM)
48.58%
Valuation
Price to revenue (TTM)
20.68
Price to book
-4.76
Price to tangible book (TTM)
-4.65
Price to free cash flow (TTM)
-7.463
Growth
Revenue change (TTM)
181.05%
Earnings per share change (TTM)
11.60%
3-year revenue growth (CAGR)
192.77%
3-year earnings per share growth (CAGR)
-9.01%
What the Analysts think about BridgeBio Pharma
Analyst Ratings
Majority rating from 15 analysts.
BridgeBio Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$211M
12,317.65%
Net income
-$35M
-79.06%
Profit margin
-16.67%
-99.83%
BridgeBio Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.98
-$1.08
-$0.96
-$0.20
-
Expected
-$0.83
-$0.82
-$0.91
-$0.71
-$1.05
Surprise
17.60%
32.42%
5.44%
-71.92%
-
BridgeBio Pharma News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
GlobeNewsWire·7 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
PRNewsWire·2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $5B as of July 26, 2024.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of July 26, 2024.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell BridgeBio Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.